Abstract Library

#1708 STREET - Somatostatin Treatment Experience Trial

Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Almquist M, Myrenfors P, Ström T, Kozlovacki G,

Keywords: somatostatin analogs, octreotide, lanreotide, quality of life, injection,

#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP

Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlovacki G, Welin S, Eriksson B, Granberg D, Gaasvik-Blomqvist L,

Keywords: pasireotide, octreotide LAR, small intestinal NET, diarrhea, VIP ,

#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors

Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Granberg D, Sandström M, Sundin A, Welin S, Kozlovacki G,

Keywords: NETs, Lutetium, radiolabelled somatostatin analogs, PRRT,